NGEN News & Events

Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.

NervGen Pharma secondary offering; price range $2.50-$3.68

NervGen Pharma Corp. announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase common shares and accompanying warrants to purchase common shares. All of the common shares, pre-funded warrants and accompanying common share warrants to be sold in the offering will be offered by NervGen. The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to advance NVG-291 through clinical studies and for general corporate and working capital purposes. Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.

"With the achievement of FDA alignment on the study parameters of RESTORE, our registrational study of NVG-291 in chronic tetraplegia, NervGen is now firmly in execution mode," said Adam Rogers, president and CEO of NervGen. "Our focus is on initiating the registrational study in mid-2026, advancing forward on behalf of the individuals living with SCI who today have no pharmacologic options capable of enabling meaningful recovery of function, independence, or quality of life. The progress we are making, including activating study sites and expanding our senior leadership team, reflect the necessary steps to advance a therapy of this magnitude toward potential approval."